Intravenous Lidocaine and the Unfinished Comparison
An editorial reading of an interrupted comparison: examine the measurements before imagining the verdict.
4 min read
Editorial inference: An editorial reading of an interrupted comparison: examine the measurements before imagining the verdict. The interesting question in this file is what would count as a convincing comparison.
The supplied registry record for NCT07770581 describes a pediatric study comparing the Buzzy device with intravenous lidocaine for pain during propofol injection. It lists the study as terminated because the principal investigator left the institution and recruitment remained incomplete. Editorial inference: that explanation identifies an interruption in study continuity; it does not establish treatment failure or global abandonment of lidocaine. The pharmaceutical obituary can stay in the drawer.
The trial assigned Buzzy to the experimental arm and intravenous lidocaine to the active comparator arm. The registry specifies randomized, parallel allocation with the outcome assessor masked. Eligible ages were 12 through 17. Its narrative envisaged 106 children. The actual enrollment field lists 49. Editorial inference: the enrollment shortfall matters when asking what analysis could be supported, but the count alone establishes neither efficacy nor statistical futility. A useful review would ask how many participants contributed usable measurements in each arm, rather than treating enrollment as a substitute for an outcome table.
The primary outcome was Buzzy's non-inferiority to intravenous lidocaine for preventing propofol injection pain. Investigators planned assessment with FLACC and the Cameron scale. The description acknowledges that FLACC was not developed specifically for propofol pain and that Cameron captures a limited range of pain expressions. These are the investigators' stated measurement limitations. The registry attributes the stop to the investigator's departure and incomplete enrollment.
Editorial inference: the methodological task is to connect those two instruments to one interpretable comparison. A reviewer should ask what difference would have counted as acceptably small, how that threshold was justified, and which scale would govern the conclusion if the instruments disagreed. Would agreement on one scale suffice, or would both need to support the same interpretation? Those are questions for a protocol and analysis plan, not invitations to invent their contents. Two scales should earn their place in the analysis rather than merely arrive as a matching set.
The registered pain assessment window spans ten minutes, with observations planned every minute from before induction through the period afterward. Heart rate and blood pressure were also planned as secondary indicators of injection pain. Editorial inference: this makes the timing of the comparison another worthwhile question. Would the analysis emphasize the highest observed pain, a particular observation, or a summary across the window? How would incomplete observations be handled? The registered schedule provides a starting point for that inquiry, but a reader should seek the intended decision rule before interpreting any eventual collection of scores. Similarly, physiological observations should be examined for their stated pain-assessment purpose rather than assumed to constitute a comprehensive safety evaluation.
The supplied registry indicates that results are not posted there. UNKNOWN: whether Buzzy met the non-inferiority objective, what the comparative pain results were, and what clinical safety outcomes occurred in this pediatric study. Editorial inference: the next useful evidence would be the analysis plan, participant accounting, and an outcome report, if available. Their availability is UNKNOWN.
Editorial inference: the separate liver-surgery publication illustrates why the endpoint deserves such attention. Its abstract describes randomized allocation in minor liver surgery. It reports 124 participants. The primary endpoint was opioid consumption during the first postoperative day. The authors report no reduction in postoperative opioid use with perioperative intravenous lidocaine. They also report lower pain scores at early assessments, with that difference absent from postoperative day one onward. Editorial inference: those findings address different measurements and time windows; neither resolves the pediatric device comparison. Publication supplies a report to examine, not proof of general efficacy or a transferable pediatric safety conclusion.
The registry identifies Ann & Robert H Lurie Children's Hospital of Chicago as lead sponsor. Ownership, licensing rights, access to underlying data, and commercial opportunity remain UNKNOWN. Editorial inference: sponsorship establishes a study role, not ownership. For a physician-curious reader, the productive follow-up is to establish whether the surviving documentation can explain the intended comparison and support an interpretable analysis. Any proposal to revisit the question should begin there, before assigning either a clinical verdict or a commercial narrative.
Sources and limits
Supplied registry receipt for NCT07770581
Supplied record of study design, enrollment, planned measurements, termination explanation, sponsor, and results-posting status; not independently verified.
Supplied publication receipt: minor liver surgery trial
Abstract-level description and findings of the separate liver-surgery trial; not evidence of outcomes in the pediatric comparison.
Explore the names behind the story
Intravenous lidocaine · Buzzy · Propofol · NCT07770581 · Ann & Robert H Lurie Children's Hospital of Chicago
Intravenous lidocaine Pediatric anesthesia Trial interpretation Propofol injection pain
Go deeper on this asset.
create a private search brief. A scoped investigation can examine the evidence and rights. This editorial article does not qualify the asset or establish availability.
Create your account to explore and watch evidence changes.